Why the study?
Familial hypercholesterolemia markedly elevates cardiovascular risk, making early detection, diagnosis, and proper management critical through updated Korean guidance.
Answers are grounded in this paper and cite their sources.
This 2022 Korean consensus statement provides updated clinical guidance on the screening, diagnosis, and pharmacological management (statins, ezetimibe, PCSK9 inhibitors) of familial hypercholesterolemia to achieve strict LDL-C reduction targets.
Familial hypercholesterolemia (FH) is the most common monogenic disorder. Due to the marked elevation of cardiovascular risk, the early detection, diagnosis, and proper management of this disorder are critical. Herein, the 2022 Korean guidance on this disease is presented. Clinical features include severely elevated low-density lipoprotein-cholesterol (LDL-C) levels, tendon xanthomas, and premature coronary artery disease. Clinical diagnostic criteria include clinical findings, family history, or pathogenic mutations in the LDLR, APOB, or PCSK9. Proper suspicion of individuals with typical characteristics is essential for screening. Cascade screening is known to be the most efficient diagnostic approach. Early initiation of lipid-lowering therapy and the control of other risk factors are important. The first-line pharmacological treatment is statins, followed by ezetimibe, and PCSK9 inhibitors as required. The ideal treatment targets are 50% reduction and <70 mg/dL or <55 mg/dL (in the presence of vascular disease) of LDL-C, although less strict targets are frequently used. Homozygous FH is characterized by untreated LDL-C >500 mg/dL, xanthoma since childhood, and family history. In children, the diagnosis is made with criteria, including items largely similar to those of adults. In women, lipid-lowering agents need to be discontinued before conception.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2022) conducted a review in Familial hypercholesterolemia. Lipid-lowering therapy (statins, ezetimibe, PCSK9 inhibitors) was evaluated. The 2022 Korean consensus statement on familial hypercholesterolemia recommends statins, ezetimibe, and PCSK9 inhibitors to achieve a 50% LDL-C reduction and targets of <70 or </dL.
Synapse has enriched 10 related papers. Consider them for comparative context: